The Latest Breaking News from FDA

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

FDA advisers this week will scrutinize what could become the first approved psychedelic drug.

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

Vapes with candy-like flavors such as “blue razz ice” and “pink lemonade” dominated the study.

Before the new oral medication, women experiencing postnatal depression were prescribed an intravenous injection which risks excessive sedation and a sudden loss of consciousness.

The tool, from telehealth company Ro, lets users report when they find the drug in stock and when there’s a shortage.

Government lawyers had told the court flights could go in late June – but then Rishi Sunak called the election

Helpful tool or harmful fad?

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…